NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (Paris:OSE) (ISIN: FR0012127173; Mnémo: OSE) announces the presentation of Phase 3 clinical results of Tedopi® today at 13:30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results